83 related articles for article (PubMed ID: 25524406)
1. Level of plasma neuregulin-1 SMDF is reduced in patients with idiopathic Parkinson's disease.
Hama Y; Yabe I; Wakabayashi K; Kano T; Hirotani M; Iwakura Y; Utsumi J; Sasaki H
Neurosci Lett; 2015 Feb; 587():17-21. PubMed ID: 25524406
[TBL] [Abstract][Full Text] [Related]
2. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of neuregulin-1β1 protects dopaminergic neurons in a mouse model of Parkinson's disease.
Carlsson T; Schindler FR; Höllerhage M; Depboylu C; Arias-Carrión O; Schnurrbusch S; Rösler TW; Wozny W; Schwall GP; Groebe K; Oertel WH; Brundin P; Schrattenholz A; Höglinger GU
J Neurochem; 2011 Jun; 117(6):1066-74. PubMed ID: 21517849
[TBL] [Abstract][Full Text] [Related]
4. Neuregulin-1 receptor tyrosine kinase ErbB4 is upregulated in midbrain dopaminergic neurons in Parkinson disease.
Depboylu C; Höllerhage M; Schnurrbusch S; Brundin P; Oertel WH; Schrattenholz A; Höglinger GU
Neurosci Lett; 2012 Dec; 531(2):209-14. PubMed ID: 23123776
[TBL] [Abstract][Full Text] [Related]
5. Sensory and motor neuron-derived factor is a transmembrane heregulin that is expressed on the plasma membrane with the active domain exposed to the extracellular environment.
Schroering A; Carey DJ
J Biol Chem; 1998 Nov; 273(46):30643-50. PubMed ID: 9804837
[TBL] [Abstract][Full Text] [Related]
6. Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease.
Salehi Z; Mashayekhi F
J Clin Neurosci; 2009 Jan; 16(1):90-3. PubMed ID: 19017558
[TBL] [Abstract][Full Text] [Related]
7. A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice.
Newell KA; Karl T; Huang XF
Neuroscience; 2013 Sep; 248():670-80. PubMed ID: 23811072
[TBL] [Abstract][Full Text] [Related]
8. Differential distribution of neuregulin in human brain and spinal fluid.
Pankonin MS; Sohi J; Kamholz J; Loeb JA
Brain Res; 2009 Mar; 1258():1-11. PubMed ID: 19150438
[TBL] [Abstract][Full Text] [Related]
9. Receptor binding and biological activity of mammalian expressed sensory and motor neuron-derived factor (SMDF).
Osheroff PL; Tsai SP; Chiang NY; King KL; Li R; Lewis GD; Wong K; Henzel W; Mather J
Growth Factors; 1999; 16(3):241-53. PubMed ID: 10372964
[TBL] [Abstract][Full Text] [Related]
10. Sensory and motor neuron-derived factor. A novel heregulin variant highly expressed in sensory and motor neurons.
Ho WH; Armanini MP; Nuijens A; Phillips HS; Osheroff PL
J Biol Chem; 1995 Jun; 270(24):14523-32. PubMed ID: 7782315
[TBL] [Abstract][Full Text] [Related]
11. Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease.
di Michele F; Longone P; Romeo E; Lucchetti S; Brusa L; Pierantozzi M; Bassi A; Bernardi G; Stanzione P
Neurol Sci; 2003 Oct; 24(3):172-3. PubMed ID: 14598072
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease.
van Dijk KD; Jongbloed W; Heijst JA; Teunissen CE; Groenewegen HJ; Berendse HW; van de Berg WD; Veerhuis R
Parkinsonism Relat Disord; 2013 Dec; 19(12):1079-83. PubMed ID: 23932065
[TBL] [Abstract][Full Text] [Related]
13. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease.
Trupp M; Jonsson P; Ohrfelt A; Zetterberg H; Obudulu O; Malm L; Wuolikainen A; Linder J; Moritz T; Blennow K; Antti H; Forsgren L
J Parkinsons Dis; 2014; 4(3):549-60. PubMed ID: 24927756
[TBL] [Abstract][Full Text] [Related]
14. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons.
Iwakura Y; Piao YS; Mizuno M; Takei N; Kakita A; Takahashi H; Nawa H
J Neurochem; 2005 May; 93(4):974-83. PubMed ID: 15857400
[TBL] [Abstract][Full Text] [Related]
15. Elevated cleavage of neuregulin-1 by beta-secretase 1 in plasma of schizophrenia patients.
Zhang Z; Cui J; Gao F; Li Y; Zhang G; Liu M; Yan R; Shen Y; Li R
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():161-168. PubMed ID: 30500411
[TBL] [Abstract][Full Text] [Related]
16. Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease.
Mashayekhi F; Mirzajani E; Naji M; Azari M
J Clin Neurosci; 2010 May; 17(5):623-7. PubMed ID: 20189394
[TBL] [Abstract][Full Text] [Related]
17. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
[TBL] [Abstract][Full Text] [Related]
18. Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients.
Mostaid MS; Lee TT; Chana G; Sundram S; Shannon Weickert C; Pantelis C; Everall I; Bousman C
Transl Psychiatry; 2017 Dec; 7(12):1280. PubMed ID: 29225331
[TBL] [Abstract][Full Text] [Related]
19. Neuregulin 1 growth factors regulate proliferation but not apoptosis of a CNS neuronal progenitor cell line.
Edwards JM; Bottenstein JE
Brain Res; 2006 Sep; 1108(1):63-75. PubMed ID: 16859650
[TBL] [Abstract][Full Text] [Related]
20. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.
Yasuda T; Fukuda-Tani M; Nihira T; Wada K; Hattori N; Mizuno Y; Mochizuki H
Exp Neurol; 2007 Aug; 206(2):308-17. PubMed ID: 17604022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
